Introduction to Cold Agglutinin Disease

Learning objectives

After completing this quiz, the learner should be able to:

describe CAD as an autoimmune hemolytic anemia involving IgM, complement, and a clonal B-cell process
distinguish primary CAD from secondary cold agglutinin syndrome at a high level
explain why cold exposure matters but does not fully define the disease
recognize how CAD differs from warm autoimmune hemolytic anemia
identify the two major therapeutic targets in CAD
explain why CAD management requires clinical judgment rather than a fixed algorithm

Which statement best describes primary cold agglutinin disease?

An IgG-mediated autoimmune hemolytic anemia caused primarily by splenic red-cell clearance

This better resembles warm AIHA, which is usually IgG-mediated and often splenic.

A clonal cold-antibody autoimmune hemolytic anemia in which IgM antibodies activate complement

Primary CAD is typically driven by monoclonal IgM antibodies produced by a small clonal B-cell population. These antibodies bind red cells at lower temperatures and activate the classical complement pathway, leading to hemolysis.

A transient infection-associated anemia caused by short-lived polyclonal antibodies

Transient infection-associated cold agglutinins are more consistent with secondary cold agglutinin syndrome.

A platelet disorder caused by cold-induced platelet aggregation

CAD is a red-cell antibody and complement disorder, not a platelet disorder.

What makes CAD distinctive among autoimmune hemolytic anemias?

It is always acute and self-limited

Primary CAD is usually chronic or relapsing, not always acute.

It is usually caused by IgG antibodies binding at 37°C

Warm AIHA is usually IgG-mediated at body temperature.

It combines antibody binding, complement activation, temperature-dependent behavior, and often a clonal B-cell source

CAD is distinctive because immune biology, complement activation, circulation, and environmental temperature interact. Most cases of primary CAD also involve a marrow-based clonal B-cell process producing pathogenic IgM.

It is primarily treated with corticosteroids

Corticosteroids are usually ineffective in CAD and should not be the default durable strategy.

Why does cold exposure matter in CAD?

Cold exposure creates the IgM clone

Cold exposure does not create the clone.

Cold exposure allows IgM antibodies to bind red cells more effectively in cooler peripheral circulation

IgM cold agglutinins bind red cells more avidly at lower temperatures, especially in peripheral circulation. Once bound, they can activate complement and contribute to hemolysis or cold-induced circulatory symptoms.

Cold exposure prevents complement activation

IgM binding can trigger complement activation.

Cold exposure causes red cells to stop producing hemoglobin

Mature red cells do not produce hemoglobin.

Why can hemolysis in CAD persist year-round, even though cold exposure worsens symptoms?

Complement activation can continue after IgM detaches from red cells in warmer central circulation

IgM may bind red cells in cooler circulation and then detach when red cells return to warmer central circulation. Complement fragments can remain on the red-cell surface, marking cells for destruction. This helps explain why hemolysis may persist beyond obvious cold exposure.

Red cells remain permanently frozen in the spleen

This is not the mechanism of CAD.

Cold exposure is irrelevant to CAD

Cold exposure is relevant, but it is not the whole disease.

Hemolysis in CAD is caused only by winter temperatures

CAD may worsen in winter, but hemolysis can persist year-round.

Which finding most helps distinguish CAD from typical warm autoimmune hemolytic anemia?

CAD is usually IgM- and complement-mediated, whereas warm AIHA is usually IgG-mediated

CAD is typically mediated by IgM cold agglutinins that activate complement. Warm AIHA is usually mediated by IgG antibodies and often involves splenic clearance.

CAD is caused by platelet antibodies, whereas warm AIHA is caused by red-cell antibodies

Both are red-cell antibody disorders.

CAD always resolves without treatment

Primary CAD is often chronic.

CAD responds reliably to corticosteroids

Corticosteroids are usually ineffective in CAD.

Which two biological targets shape modern treatment strategy in CAD?

Platelets and fibrinogen

CAD is not primarily a coagulation-factor or platelet disorder.

Iron absorption and kidney function

Iron and kidney function may matter clinically but are not the defining treatment targets.

The IgM-producing B-cell clone and the classical complement pathway

CAD treatment reflects two major disease axes. Clone-directed therapy aims to reduce pathogenic IgM production. Complement-directed therapy aims to interrupt the hemolytic effector pathway.

The spleen and neutrophils

Splenectomy is generally biologically mismatched to typical CAD.

Why is CAD management described as strategic rather than algorithmic?

Because the biology of CAD is unknown

Much of the core biology is well understood.

Because every patient should receive the same therapy

CAD treatment is not one-size-fits-all.

Because treatment depends on symptoms, hemolysis, circulatory burden, disease tempo, comorbidity, and patient priorities

The mechanism of CAD is increasingly well understood, but the best decision for a given patient depends on context. Some patients need rapid control of hemolysis, some may benefit from clone-directed therapy, and others may be best managed with observation and supportive care.

Because treatment is never needed

Many patients do require treatment, but not all do.

Closing Note

This introductory quiz is meant to orient the learner to the whole CAD module. The central idea is that CAD sits at the intersection of IgM antibody biology, classical complement activation, cold-sensitive circulation, clonal B-cell disease, and patient-centered decision-making.

The rest of the module builds outward from that framework.

1 / 9